ARK Genomic Revolution ET... (ARKG)
20.67
-0.13 (-0.62%)
At close: Apr 17, 2025, 3:59 PM
20.87
0.97%
After-hours: Apr 17, 2025, 07:50 PM EDT
-0.62% (1D)
| Bid | 20.48 |
| Market Cap | 941.69M |
| AUM | 1.31B |
| NAV | 24.27 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Shares Out | 45.56M |
| Inception Date | Oct 31, 2014 |
| Ask | 20.89 |
| Volume | 2.04M |
| Open | 20.64 |
| Previous Close | 20.80 |
| Day's Range | 20.36 - 20.86 |
| 52-Week Range | 17.50 - 31.16 |
| Holdings | 41 |
| Expense Ratio | 0.75% |
About ARKG
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
Asset Class Equity
Ticker Symbol ARKG
Inception Date Oct 31, 2014
Provider ARK
Website Fund Home Page
Top 10 Holdings 64.12% of assets
| Name | Symbol | Weight |
|---|---|---|
| Twist Bioscience Cor... | TWST | 9.24% |
| Crispr Therapeutics ... | CRSP | 8.01% |
| Tempus Ai, Inc. | TEM | 7.38% |
| Adaptive Biotechnolo... | ADPT | 6.58% |
| Natera, Inc. | NTRA | 6.42% |
| Guardant Health, Inc... | GH | 6.38% |
| Recursion Pharmaceut... | RXRX | 6.35% |
| Schrödinger, Inc. | SDGR | 4.85% |
| Caredx, Inc | CDNA | 4.75% |
| Veracyte, Inc. | VCYT | 4.16% |
Dividends Dividend Yield 0.64%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Dec 29, 2021 | $0.3824 | Dec 31, 2021 |
| Dec 29, 2020 | $0.7901 | Dec 31, 2020 |
| Dec 27, 2019 | $1.0539 | Dec 31, 2019 |
| Dec 27, 2018 | $0.4663 | Dec 31, 2018 |
| Dec 27, 2017 | $0.3277 | Dec 29, 2017 |
2 months ago · seekingalpha.com
ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum TrendsI maintain a buy rating on ARK Genomic Revolution ETF (ARKG) due to improving momentum, potential lower interest rates, and a favorable M&A environment in 2025. Despite a 20% decline in 2024, ARKG's t...
